Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Gastrointestinal 2Sarcoma 1NET 1Head & Neck 1Endocrine 1

Conditions

Sarcoma 4Osteosarcoma 3Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1

Interventions

Gemcitabine 5Docetaxel 4tislelizumab 3Bortezomib 3spartalizumab 2pembrolizumab 2Nivolumab 2Irinotecan 2Filgrastim 2Cisplatin 2Capecitabine 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1tinostamustine 1talazoparib 1surufatinib 1regorafenib 1pazopanib 1pamiparib 1liposomal doxorubicin 1isophosphamide mustard 1futibatinib 1etoposide phosphate 1entinostat 1cc-486 1cabozantinib 1atezolizumab 1anlotinib 1Vinorelbine 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × surufatinib × Sarcoma × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡